Business Context and Reporting Period
Company: Halozyme Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date: December 12, 2005
Context: The company entered into a Placement Agent Agreement for a registered direct offering of common stock.
Key Financial Metrics
This filing details a capital raise rather than periodic operating results. Specific metrics include:
- Shares Offered: 9,171,429 shares of common stock.
- Offering Price: $1.75 per share.
- Gross Proceeds: Approximately $16.1 million.
- Expected Closing Date: December 16, 2005.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the execution of a definitive agreement to raise capital via a registered direct offering. This transaction represents a significant increase in the company's equity capital pending closing.
Guidance, Outlook, and Use of Proceeds
Management indicated the net proceeds from the offering will be allocated to:
- Research and development activities.
- Clinical trials.
- Other working capital and general corporate purposes.
The offering is subject to the satisfaction of customary closing conditions. No specific forward-looking financial guidance or risk factors beyond standard closing conditions were detailed in this specific text.
Investor Verification Checklist
- Verify the actual closing of the offering on or around December 16, 2005.
- Confirm the final number of shares issued and net proceeds after deducting placement agent fees and expenses.
- Review the prospectus supplement (Rule 424(b)(5)) for detailed risk factors and dilution impact.
- Monitor subsequent filings for updates on the utilization of funds for clinical trials and R&D.